SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
Consumer
Consumer
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (18.2) | (12.1) | (56.2) |
Relative | (16.9) | (18.6) | (58.6) |
52 week high/low | €19.6/€9.0 |
SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.